Figure 1
The levels of EMR2 expressions on neutrophil correlated with different cirrhotic stage (A) Neutrophils were purified by PolymorphPrepTM (Axis–Shield PoC, Oslo, Norway) and washed three times with freshly phosphate- buffered saline (PBS) (Sigma Aldrich, St. Louis, MO) at 4 °C and suspended in RPMI-1640 (Sigma Lifesciences, USA). By neutrophil-specific FSC/SSC gating strategy and reconfirmed by neutrophil phenotypic marker CD 11b (>97% cell purity, Fig. 1A upper part), measurements of the EMR2 expressions on neutrophils from healthy controls and liver cirrhotic patients were done as compared to the negative control (Fig. 1A lower part). The mean MFI of this isotype control was less than 10. That means when the MFI above 10, it would be positive for the EMR-2 expression. (B) When sub-grouping cirrhotic patents according to CTP class, an increasing EMR2 expression on neutrophil was noted as the severity of liver cirrhosis progress when comparing that with healthy volunteers (MFI of EMR2: Child-Turcotte-Pugh A vs. B vs. C vs. healthy volunteers: 23.74 ± 11.15 vs. 33.97 ± 18.00 vs. 39.89 ± 24.95 vs. 18.38 ± 7.74; p < 0.0001) (C) The expression level of EMR2 on neutrophil significantly correlated with CTP scores by linear regression (r2 = 0.1144, P = 0.0006)
